<DOC>
	<DOCNO>NCT01577186</DOCNO>
	<brief_summary>The purpose study explore relationship achieve symptomatic remission status mean 8 item Positive Negative Syndrome Scale ( PANSS ) , personal social functioning mean Personal Social Performance ( PSP ) scale participant treat flexibly dose paliperidone ER .</brief_summary>
	<brief_title>Symptomatic Remission Social Function Participants Treated With Paliperidone Extended Release ( ER )</brief_title>
	<detailed_description>This open label ( people know identity intervention ) , multicenter ( one hospital medical school team work medical research study ) prospective ( study follow participant forward time ) 12-week study . Participants either in- outpatient . The total study duration 12 week participant include follow visit : Screening , Week 0 , 4 , 8 , 12 ( end treatment early withdrawal ) . Throughout study , participant receive paliperidone ER flexible dosing range 3 12 milligram per day ( mg/day ) . Efficacy primarily evaluate PANSS PSP scale . Participants ' safety also monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participants meet Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criterion schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) Participant drug naive participant 's previous treatment consider unsuccessful due one follow reason : lack efficacy , lack tolerability safety , lack compliance and/or reason Participants legally acceptable representative sign informed consent document indicate understand purpose procedure require study willing participate study Women must postmenopausal least 1 year , surgically sterile , abstinent , , sexually active , agree practice effective method birth control entry throughout study must negative urine pregnancy test screening Participants use clozapine , paliperidone extend release ( ER ) , conventional depot neuroleptic Risperdal CONSTA last 3 month Participants serious unstable medical condition , include know clinically relevant laboratory abnormality Participants history neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness ) Participants know hypersensitivity paliperidone ER risperidone Participants inability swallow whole study medication tablet aid water</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Extended Release</keyword>
</DOC>